149 related articles for article (PubMed ID: 28279153)
1. The association between biochemical control and cardiovascular risk factors in acromegaly.
Carmichael JD; Broder MS; Cherepanov D; Chang E; Mamelak A; Said Q; Neary MP; Bonert V
BMC Endocr Disord; 2017 Mar; 17(1):15. PubMed ID: 28279153
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center.
Carmichael JD; Broder MS; Cherepanov D; Chang E; Mamelak A; Said Q; Neary MP; Bonert V
BMC Endocr Disord; 2017 Aug; 17(1):49. PubMed ID: 28778166
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly: presentation, morbidity and treatment outcomes at a single centre.
Anagnostis P; Efstathiadou ZA; Polyzos SA; Adamidou F; Slavakis A; Sapranidis M; Litsas ID; Katergari S; Selalmatzidou D; Kita M
Int J Clin Pract; 2011 Aug; 65(8):896-902. PubMed ID: 21679284
[TBL] [Abstract][Full Text] [Related]
4. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.
Abreu A; Tovar AP; Castellanos R; Valenzuela A; Giraldo CM; Pinedo AC; Guerrero DP; Barrera CA; Franco HI; Ribeiro-Oliveira A; Vilar L; Jallad RS; Duarte FG; Gadelha M; Boguszewski CL; Abucham J; Naves LA; Musolino NR; de Faria ME; Rossato C; Bronstein MD
Pituitary; 2016 Aug; 19(4):448-57. PubMed ID: 27279011
[TBL] [Abstract][Full Text] [Related]
5. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.
Caron P; Broussaud S; Bertherat J; Borson-Chazot F; Brue T; Cortet-Rudelli C; Chanson P
J Clin Endocrinol Metab; 2010 Oct; 95(10):4680-7. PubMed ID: 20660047
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.
Ramos-Leví AM; Marazuela M
Endocrine; 2017 Feb; 55(2):346-359. PubMed ID: 28042644
[TBL] [Abstract][Full Text] [Related]
7. Adolescent acromegaly and decreased arterial distensibility despite successful treatment.
Bassareo PP; Marras AR; Mercuro G
Clin Endocrinol (Oxf); 2012 Jul; 77(1):79-85. PubMed ID: 22182355
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine levels in acromegaly patients.
Hekimsoy Z; Ozmen B; Ulusoy S
Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
[TBL] [Abstract][Full Text] [Related]
9. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
10. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.
Mercado M; Gonzalez B; Vargas G; Ramirez C; de los Monteros AL; Sosa E; Jervis P; Roldan P; Mendoza V; López-Félix B; Guinto G
J Clin Endocrinol Metab; 2014 Dec; 99(12):4438-46. PubMed ID: 25210882
[TBL] [Abstract][Full Text] [Related]
11. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease.
Davi' MV; Dalle Carbonare L; Giustina A; Ferrari M; Frigo A; Lo Cascio V; Francia G
Eur J Endocrinol; 2008 Nov; 159(5):533-40. PubMed ID: 18765561
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
13. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.
Colao A; Ferone D; Marzullo P; Lombardi G
Endocr Rev; 2004 Feb; 25(1):102-52. PubMed ID: 14769829
[TBL] [Abstract][Full Text] [Related]
14. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography.
Cannavo S; Almoto B; Cavalli G; Squadrito S; Romanello G; Vigo MT; Fiumara F; Benvenga S; Trimarchi F
J Clin Endocrinol Metab; 2006 Oct; 91(10):3766-72. PubMed ID: 16835284
[TBL] [Abstract][Full Text] [Related]
15. [The OASIS study: therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies].
Luque-Ramírez M; Carreño A; Alvarez Escolá C; del Pozo Picó C; Varela da Costa C; Fajardo Montañana C; Gilabert M; Webb S;
Endocrinol Nutr; 2011 Nov; 58(9):478-86. PubMed ID: 22032858
[TBL] [Abstract][Full Text] [Related]
16. Identification of acromegalic patients at risk of developing colonic adenomas.
Bogazzi F; Cosci C; Sardella C; Costa A; Manetti L; Gasperi M; Rossi G; Bartalena L; Martino E
J Clin Endocrinol Metab; 2006 Apr; 91(4):1351-6. PubMed ID: 16449330
[TBL] [Abstract][Full Text] [Related]
17. Cardiac effect of thyrotoxicosis in acromegaly.
Marzullo P; Cuocolo A; Ferone D; Pivonello R; Salvatore M; Lombardi G; Colao A
J Clin Endocrinol Metab; 2000 Apr; 85(4):1426-32. PubMed ID: 10770177
[TBL] [Abstract][Full Text] [Related]
18. 5 Long-term acromegaly and associated cardiovascular complications: a case-based review.
Colao A
Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23 Suppl 1():S31-8. PubMed ID: 20129192
[TBL] [Abstract][Full Text] [Related]
19. Effect of transsphenoidal surgery on sleep apnoea in acromegaly.
Sze L; Schmid C; Bloch KE; Bernays R; Brändle M
Eur J Endocrinol; 2007 Mar; 156(3):321-9. PubMed ID: 17322492
[TBL] [Abstract][Full Text] [Related]
20. Emerging trends in the diagnosis and treatment of acromegaly in Canada.
Vallette S; Ezzat S; Chik C; Ur E; Imran SA; Van Uum S; Rivera J; Caspar-Bell G; Serri O
Clin Endocrinol (Oxf); 2013 Jul; 79(1):79-85. PubMed ID: 23190441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
